Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 17/20 | 0.53 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.53 |
| ▸ | AKT1 | P31749 | 12/20 | 0.52 |
| ▸ | MTOR | P42345 | 12/20 | 0.52 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.44 |
| ▸ | PIK3R5 | Q8WYR1 | 2/20 | 0.44 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.44 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.44 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
| ▸ | PRKDC | P78527 | 1/20 | 0.44 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.44 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.44 |
| ▸ | SMG1 | Q96Q15 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL881114 | 0.90 | PIK3R1 (0.46) | PIK3CAMAP3K12AKT1MTORPIK3CG | |
| SCHEMBL2674742 | 0.84 | CLK2 (0.52) | PIK3CAMAP3K12AKT1MTORPIK3CG | |
| SCHEMBL10327713 | 0.83 | PIK3CA (0.64) | PIK3CAMAP3K12MTORPIK3CGPIK3CB | |
| SCHEMBL855470 | 0.81 | PIK3CA (0.43) | PIK3CAAKT1MTORPIK3CGPIK3CB | |
| SCHEMBL10327656 | 0.76 | PIK3CA (0.64) | PIK3CAMAP3K12MTORPIK3CGPIK3CB | |
| SCHEMBL855692 | 0.76 | CLK2 (0.52) | PIK3CAAKT1MTORPIK3CGPIK3R5 | |
| SCHEMBL12091754 | 0.75 | PIK3CA (0.46) | PIK3CAMTORPIK3CGPIK3CBPIK3CD | |
| SCHEMBL10327768 | 0.75 | PIK3CA (0.58) | PIK3CAMTORPIK3CGPIK3R5PIK3CB | |
| SCHEMBL881132 | 0.74 | PIK3CA (0.70) | PIK3CAMAP3K12AKT1MTOR | |
| SCHEMBL881133 | 0.74 | PIK3CA (0.54) | PIK3CAMAP3K12AKT1MTORPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173647-B2 | PI 3-kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2012-05-08 | — | — | US | disclosed |
| US-8173647-B2 | PI 3-kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2012-05-08 | — | — | US | disclosed |
| US-8173647-B2 | PI 3-kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2012-05-08 | — | — | US | disclosed |
| EP-2118087-B1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-03-28 | — | — | EP | disclosed |
| US-20100048547-A1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2010-02-25 | — | — | US | disclosed |
| US-20100048547-A1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2010-02-25 | — | — | US | disclosed |
| US-20100048547-A1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2010-02-25 | — | — | US | disclosed |
| EP-2132215-A2 | COMPOUNDS FOR PREVENTING OR TREATING VIRAL INFECTIONS AND METHODS OF USE THEREOF | The Governors of the University of Alberta (CA) | 2009-12-16 | — | — | EP | disclosed |
| EP-2118087-A1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | Novartis Ag (CH) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008104893-A2 | COMPOUNDS FOR PREVENTING OR TREATING VIRAL INFECTIONS AND METHODS OF USE THEREOF | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (US) | 2008-09-04 | — | — | WO | disclosed |
| WO-2008098058-A1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008098058-A1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048547-A1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | PI4KA, PI4KB, PI4K2A | PIK3CA 5/4885MAP3K12 60/4885AKT1 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.